CEO of Raygent Associates
Contributor's Links: Raygent

Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 35 years executive experience including Abbott and JNJ and has been involved three successful start-ups. Before starting Raygent and other companies he was also a ... more

ALL CONTRIBUTIONS

Bear Market Rally Lifts HealthCare Stocks Off Bottom
Clearly we are in a biotech bear market with both diagnostics and vaccine revenues stalled. If gene editing stocks cannot offer breakthrough clinical news then stick with large cap biopharma.
Read
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing.
Read
How Is It Going With The Big Biopharma Earnings Week?
Abbott and JNJ kicked off healthcare earnings last week and the results were just OK.
Read
Healthcare Stocks Lead The Way Up As The Market Fades
With inflation and energy costs soaring, the Fed ever threatening with higher rates and headlines from the war in Ukraine investors are seeking more defensive positions.
Read
Good Entry Point For Biotech Stocks
Life science and biotech stocks had a good week with the most well-known ETFs up 3-4% for the week and off recent bottoms.
Read
Biotech Funds And ETFs Continue To Lag
It’s no secret that market sectors driving inflation are leading the market. With the US economy still strong and the War in Ukraine limiting supply of nat gas and raw materials, producer costs are rising.
Read

Comments

Latest Comments
Regulatory News For Rare Disease Products - Hot Stocks: BLUE, ICPT, SRPT
7 years ago

Getting trial information and following them is the hard part as it takes too much time. Just sett up the stocks in a Yahoo portfolio and track daily. The WEB site of the Company usually lets you know if trial results are coming in and when.

In this article: BLUE, ICPT, SRPT
Biotech Buzz Is Broken
7 years ago

Here is the YTD for KITE down 4.7%:

www.google.com/finance

In this article: JUNO, KITE, GILD, REGN
2015 Biotech Stock Preview: Rhythms Of The “PermaBull”
7 years ago

prefer a fund like FBIOX but XBI will work when the market heats up

In this article: XLV, FBT, FBIOX, GILD
1 to 3 of 3 comments

STOCKS I FOLLOW

TWEETS

PERSONAL BLOG

Latest Posts
Biotech Investing Strategy For 2020: Part I… Update-1 Jan 24
We remain on hold for taking on new positions. Biotech and healthcare stocks have made nice gains so let’s get through the earnings cycle.
Asco Rally Fizzles: The Nascent Rally In Biotech Stocks Fades
ASCO Rally Fizzles Two Weeks ahead of May 31-June 4 Meeting: XBI down 0.9% to $83.

Work Experience

CEO
Raygent Associates
January 1990 - Present (33 years)
Biotechnology Intelligence www.raygent.com

Education

Penn State University
BS
Biochemistry
Rutgers University
MBA
Business

Publications